Fundz

Milestone Pharmaceuticals Announces $125 Million Strategic Financing With Rtw Investments To Support The Advancement Of Etripamil For Psvt

PUBLIC · MISTMar 28, 2023

Amount Raised

$125 Million

Round Type

Venture

MontrealBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates ("RTW"). Proceeds from this tailored financing, together with $64.6 million of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund Milestone's operations into the middle of 2025, including the potential approval and launch of etripamil. Etripamil is the Company's investigational calcium channel blocker envisioned to empower patients with paroxysmal supraventricular tachycardia (PSVT) to treat their attacks outside of the emergency department.

Quick answer

Milestone Pharmaceuticals raised $125 Million in a funding round, dated March 28, 2023. Milestone Pharmaceuticals is based in Montreal, Quebec, Canada.

How much did Milestone Pharmaceuticals raise?
Milestone Pharmaceuticals raised $125 Million in a funding round on March 28, 2023.
What does Milestone Pharmaceuticals do?
Thank you for your interest in Milestone Pharmaceuticals.
Where is Milestone Pharmaceuticals based and how big is it?
Milestone Pharmaceuticals is based in Montreal, Quebec, Canada.
Who are the decision-makers at Milestone Pharmaceuticals?
Fundz holds 1 contact at Milestone Pharmaceuticals. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Milestone Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Decoy Therapeutics Inc. raised $6M on May 11, 2023.
  • Mezzion Pharma raised $40M (Funding Round) on April 25, 2023.
  • OnKure Therapeutics raised $57M on March 24, 2023.
  • Azora Therapeutics, Inc. (DE) raised $62K (Pre-Seed) on February 23, 2023.
  • Disc raised $63M (Funding Round) on February 14, 2023.
  • Provention Bio raised $35M on February 13, 2023.

Who to call at Milestone Pharmaceuticals, and when

A new round usually means Milestone Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Milestone Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Milestone Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Milestone Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Milestone Pharmaceuticals

Location

Montreal, Quebec, Canada

About

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Milestone Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts25 people are listed at Milestone Pharmaceuticals. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Milestone Pharmaceuticals's next move

See what Strategic adds

Milestone Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.